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Illness Associated with Red Tide -Nassau County, Florida, 2007
A "red tide" is a harmful algal bloom that occurs when toxic, microscopic algae in seawater proliferate to a higher-than normal concentration (i.e., bloom), often discoloring the water red, brown, green, or yellow. Red tides can kill fish, birds, and marine mammals and cause illness in humans (1) . Florida red tide is caused by the dinoflagellate Karenia brevis, which produces toxins called brevetoxins and is most com monly found in the Gulf of Mexico; however, K. brevis blooms also can occur along the Atlantic coast. On September 25, 2007, a cluster of respiratory illnesses was reported to the Nassau County Health Department (NCHD) in northeast ern Florida. All of the ill persons were employed at a beach restoration worksite by a dredging company operating at Fernandina Beach; they reported symptoms of eye or respira tory irritation (e.g., coughing, sneezing, sniffling, and throat irritation). NCHD and the Florida Department of Health promptly conducted epidemiologic and environmental inves tigations and determined the illnesses likely were associated with exposure to a red tide along the Atlantic coast. These actions highlight the importance of rapid investigation of health concerns with potential environmental causes to enable timely notification of the public and prevent further illness.
Epidemiologic Investigation
The dredging company had been contracted by the U.S. Army Corps of Engineers to clear a channel for military sub marines to navigate the Amelia River. During September 25-29, as part of this operation, the company was dredging material off the ocean floor from a ship located 3 miles off shore, near the mouth of the river. The dredged material was pumped through a pipe from the ship to the beach worksite. Approximately 50 dredging company workers were stationed aboard the ship and 13 at the beach worksite, where they redistributed the piped mix of sediment on the beach. All of the dredging company employees worked 12-hour shifts. Ship workers spent a greater portion of their shifts working indoors than did beach workers and had varying levels of exposure to outdoor elements.
On September 25, after receiving the initial reports of res piratory illness among the dredging company workers, NCHD staff members suspected the cause might be exposure to a chemical toxin. However, when staff members visited the Fernandina Beach worksite on the same day, they observed dead fish and detected the characteristic odor of brevetoxin, the toxin produced naturally by K. brevis. During September 25-26, NCHD conducted interviews with workers in two groups: those working at the beach worksite and those work ing aboard the company ship. The interviews used a standard questionnaire for outbreaks to assess exposure to dredging materials, occupational and recreational water exposure, travel history, medical history, and current health status. Ten of the 13 beach workers with daytime exposure history (the other three worked only at night) were interviewed, followed by the first 10 workers who were available on the ship. Because of logistical difficulties, additional workers on the ship could not be interviewed.
Mean age of the 20 dredging company workers was 45 years (range: 23-66 years); 90% were male. Six workers reported preexisting health conditions, including two with asthma. Nine of the 20 reported a recent history of smoking. The 20 work ers reported experiencing symptoms of respiratory or eye irri tation beginning September 16, when the dredging operation began. Predominant symptoms were coughing (12 workers), throat irritation (12), eye irritation (11), sneezing (11), and sniffling (10) ( Table 1) . None of the workers required medi cal care or experienced impairment of their ability to do their jobs. Several reported abrupt onset and resolution of their symptoms upon arrival and departure each day from the beach worksite. During September 25-29, additional reports of respiratory irritation were received by public health agencies from per sons along Florida's Atlantic coast, up to 200 miles south of Fernandina Beach. Also during this period, approximately 15-20 reports were received daily by NCHD from beachgoers with symptoms of respiratory illness.
Environmental Assessment
On September 25, water samples were collected from the Atlantic Ocean near the Fernandina Beach shoreline for evalu ation by the Fish and Wildlife Research Institute of the Florida Fish and Wildlife Conservation Commission. Light micros copy was performed to assess algal species composition and abundance.
The water samples from near the Fernandina Beach worksite first revealed K. brevis on September 25. Within 2 weeks, samples with K. brevis had been collected from additional lo cations up to 200 miles to the south (2) . The initial water samples had "medium" levels of K. brevis (100,000 to <1,000,000 cells/L), which can cause respiratory irritation and fish kills (Table 2) . However, September 26, water samples collected in Jacksonville, 35 miles south of Fernandina Beach, had "high" levels (>1,000,000 cells/L), which can cause sea water discoloration in addition to respiratory irritation and probable fish kills. Onshore wind patterns likely facilitated the transport of aerosolized brevetoxins, resulting in exposure to beachgoers.
On September 29, a storm with prolonged wind, rain, and flooding struck northeast Florida, and public reports of respi ratory symptoms began to decline. Water samples collected after September 29 detected "low a" levels of K. brevis (>1,000 to <5,000 cells/L) and "present" levels (<1,000 cells/L), indi cating that the storm likely contributed to dissipation of the red tide (Table 2) . On November 8, all five water samples collected in Nassau County had cell counts of zero (3).
Editorial Note:
The initial detection of the 2007 northeast Florida red tide described in this report was unusual because public health authorities were first alerted by a cluster of reported symptoms of human respiratory illness among dredg ing workers rather than by more common means (e.g., obser vation of dead fish or birds, detection of contaminated seafood, or use of satellite imagery or routine beach water sampling). Upon initial investigation of the human illnesses, NCHD observed dead fish and detected the odor of brevetoxin, both indications of red tide. Water sampling confirmed that an ongoing red tide bloom was in the proximity. Because only a small convenience sample of workers could be interviewed on the dredging ship, no conclusions can be drawn about the relative prevalence of red tide symptoms at the two worksites. However, the results suggest that symptoms occurred more frequently among beach workers. During red tides, symptoms are frequently more intense in persons exposed on beaches, because of aerosolization of brevetoxins in beach surf (4) .
Wildlife species have been particularly valuable sentinels for human brevetoxin illness. In the past, the Florida Department of Health has used reports of dead fish or birds (which eat contaminated fish) as an early warning mechanism for red tide blooms (5) . During the red tide event described in this report, dead sea turtles were observed on Nassau County beaches. Brevetoxin also accumulates in molluscan shellfish and is associated with human neurotoxic shellfish poisoning when contaminated seafood is ingested (6) . Shellfish beds in Florida coastal waters are sampled routinely for brevetoxin.
Studies attempting to assess the human health effects of red tide blooms have been reported. One study, in Sarasota, Florida, found a 19% increase in the rate of pneumonia cases diagnosed during a 3-month onshore red tide event and, among coastal residents, a 54% higher rate of diagnoses of respiratory illness (pneumonia, bronchitis, asthma, and upper airway disease) (7) . Other studies have found signifi cant measureable adverse changes in the lung function of asthma patients after exposure to brevetoxins (6, 8) .
Red tide blooms have been uncommon in northeastern Florida, occurring with much greater frequency in the Gulf of Mexico. Florida red tide was first documented on the Atlantic coast in 1972, south of Fernandina Beach, and further south in Jacksonville in 1980 and 1999 (9) . Florida records indicate that, before the 2007 bloom, K. brevis had not been detected in Nassau County since 1953; that detection was not associ ated with a red tide event.
In addition to the limited number of interviews with the ship workers, the findings in this report are subject to at least two other limitations. First, assessment of symptom onset dates was not possible because symptom-specific onset dates were not collected. Second, systematic collection of data on symp toms of other persons in the area of the bloom was not pos sible; therefore, the effects of the red tide event among populations other than the dredging company workers (e.g., beachgoers) could not be assessed.
During this red tide event, prompt investigation of a small cluster of symptoms led to quick identification of the K. brevis bloom. This public health vigilance enabled authorities to take immediate action to issue advisories and otherwise alert the public to an illness of environmental etiology. 
West Nile Virus ActivityUnited States, 2007
West Nile virus (WNV) is the leading cause of arboviral en cephalitis in the United States. Originally identified in Africa in 1937, WNV was first detected in the western hemisphere in 1999 in New York City. Since then, WNV has caused seasonal epi demics of febrile illness and neurologic disease in the United States. This report summarizes national WNV surveillance data for 2007. WNV transmission to humans or animals expanded into 19 coun ties that had not reported transmission previously and recurred in 1,148 counties where transmission had been reported in pre vious years. A total of 1,227 cases of WNV neuroinvasive disease (WNND) and 117 deaths were reported. These findings highlight the need for ongoing surveillance, mosquito control, promotion of personal protection from mosquito bites, and research into addi tional prevention strategies, including a WNV human vaccine.
WNV data are reported to CDC through ArboNET, an Internet-based arbovirus surveillance system managed by state health departments and CDC. State and local health depart ments 1) collect reports from health-care providers and clini cal laboratories regarding cases of WNV disease in humans; 2) collect reports of WNV presumptive viremic blood donors (PVDs)* from blood collection agencies; 3) collect and test dead birds, often focusing on corvids (e.g., crows, jays, and magpies), which have high mortality attributed to WNV infection; 4) collaborate with veterinarians to collect reports of WNV infection in nonhuman mammals; and 5) collect mosquitoes to test for evidence of WNV infection. Human WNV disease cases are classified as 1) WNND (i.e., meningi tis, encephalitis, or acute flaccid paralysis); 2) West Nile fever (WNF), which is symptomatic WNV disease that does not affect the nervous system; or 3) an unspecified clinical syn drome. WNF reporting is highly variable by jurisdiction, depending on the level of interest in reporting and use of diagnostic testing; therefore, most of this report focuses on WNND cases, which are thought to be more consistently iden tified and reported because of the severity of the illness.
Human Surveillance
During 2007, a total of 3,630 cases of WNV disease in humans were reported from 775 counties in 44 states (i.e., 25% of the 3,142 counties in the United States). Of these cases, 1,227 (34%) were WNND, 2,350 (65%) were WNF, and 53 (1%) were unspecified clinical syndromes. A total of 352 PVDs were identified through routine screening of the blood supply. Of these PVDs, 281 (80%) were asymptom atic, five (1%) subsequently developed WNND, and 66 (19%) subsequently had WNF.
Overall, the incidence of WNND in the United States was 0.4 per 100,000 population. The highest incidence of WNND occurred primarily in the west-central United States ( Figure 1) ; the five states with highest incidence were North Dakota (7.7 cases per 100,000 residents), South Dakota (6.2), Wyoming (4.6), Montana (4.0), and Colorado (2.2). Among all states, WNND peaked during the first week in August, and 1,086 (89%) cases were reported during July-September (Figure 2 ). This seasonality was consistent with trends observed in the preceding 7 years.
Of the 1,227 WNND cases, 729 (59%) occurred in males. The median age of patients was 57 years (range: 1 month-97 years), with increasing incidence among older age groups ( Figure 3) . Overall, 1,089 (89%) patients were hospitalized (median age: 59 years; range: 1 month-97 years), and 117 (10%) died (median age: 77 years; range: 43-96 years). A total of 765 (62%) WNND cases were classified as encephali tis, 452 (37%) as meningitis, and 63 (5%) as acute flaccid * A PVD is a person whose blood tested positive when screened for the presence of WNV. PVDs are followed up by the blood collection agency with additional tests to verify their infection. Some PVDs go on to develop symptoms after donation, at which point they are considered to have WNV disease. paralysis; 53 of these cases were classi fied as acute flaccid paralysis coincident with encephalitis or meningitis. . The relative stability in the number of reported WNND cases during the past 4 years likely represents endemic WNV transmission in the continental United States. However, because of variation in vectors, avian amplifying hosts, human activity, and envi ronmental factors (e.g., temperature and rainfall), predicting future WNV transmission intensity is difficult (3, 4) . Reported cases of WNND are thought to be the most accu rate indicator of WNV activity in humans. WNND report ing is thought to be more complete because of substantial associated morbidity and mortality, whereas WNF likely is underdiagnosed and underreported. Serologic surveys indi cate that approximately 20% of WNV infections result in WNF and 0.7% of WNV infections result in WNND (5 (7). This illustrates the wide annual variability and focality of WNV transmission. Human WNV infection was identified for the first time in Puerto Rico in 2007 among three asymptomatic blood donors (8) .
Animal Surveillance
ArboNET integrates arboviral diagnostic testing and report ing to produce timely, actionable data that public health pro fessionals use to tailor effective prevention and control messages at the local level. Continued surveillance is important in moni toring potential changes in WNV epidemiology and for pro viding early warning for local WNND outbreaks. In addition, ArboNET is well positioned to help identify and manage future introductions of exotic arboviruses. For example, cases of ill travelers entering the United States who are likely viremic with nonendemic arboviruses (e.g., dengue virus and chikungunya virus) are reported to ArboNET (9) .
WNV vaccines are licensed for use in horses and are being evaluated currently in phase 2 human clinical trials (10) . Because no WNV vaccine is available currently for use in humans, prevention depends on personal protective measures. Use of repellents containing DEET, picaridin, oil of lemon eucalyptus, or IR3535 provides effective protection against mosquitoes. Long-sleeved shirts, long pants, and socks pro vide barrier protection against mosquito bites, and many fab rics can be treated with permethrin to provide an additional level of protection. Avoiding outdoor exposure during dusk and dawn, when Culex mosquito species are more active, will decrease the likelihood of WNV exposure. Household mea sures, such as installing and repairing window screens and covering or draining water-holding containers to reduce mos quito breeding sites, can decrease further the risk for WNV exposure.
Additional information on effective prevention of WNV infection is available from CDC at http://www.cdc.gov/ ncidod/dvbid/westnile/index.htm. An overview of current year WNV transmission activity is available at http://diseasemaps. usgs.gov/wnv_us_human.html.
Erratum: Vol. 57, No. RR-4
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